Condition · Metabolism and Endocrine
HIV-Associated Lipodystrophy
00
Background biology
The condition is influenced by antiretroviral exposure, altered adipocyte biology, endocrine factors and individual susceptibility.
01
Evidence-ranked peptides
| Peptide | Use | Evidence |
|---|---|---|
| Tesamorelin Tesamorelin is a regulated peptide medicine with established evidence in defined indications. | HIV-Associated Lipodystrophy strong | Human5/5 Animal0/5 Safety4/5 4 verified refs |
02
Current standard management
conventional medicineManagement includes HIV specialist review, antiretroviral optimisation when appropriate, lifestyle support and indication-specific licensed treatment.
Medical disclaimer —Standard-of-care information is educational only. Do not change or start treatment based on Atlas content. Always consult a qualified clinician for personal medical decisions.
04
Linked mechanisms
biological pathways discussed for this condition- Growth hormone-releasing factor signallinglimited
- Growth hormone axislimited
05
Research gaps
what we don't know yet- ·Long-term cardiovascular outcomes
- ·Durability after treatment stops
- ·Comparative effectiveness against other strategies
03
Community observations
No approved community reports for this condition yet. Submit one.
Clinician discussion
Questions you can ask a qualified clinician
- What are the established evidence-based options for this condition?
- What monitoring is appropriate before considering any experimental intervention?
- What long-term safety data exists for peptide-based approaches?
- Are there licensed medicines relevant to my situation?
↳
Explore further
from the knowledge graphPeptides that touch this